The Group's principal activity is researching, developing and commercially exploiting stem cell technologies for therapeutic and non-therapeutic applications. The Group applies novel stem cell platform technologies in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs. Therapeutic technology is provided by c-mycER which generate genetically stable neural stem cell lines. Non-therapeutic is provided by ReNcell range of cell lines for use in research and in drug discovery applications in the pharmaceutical industry. The Group's other technology are ReNcell CX and ReNcell VM neural cell lines which are marketed worldwide.
Alacra Alerts:
Receive alerts on the latest reports on ReNeuron Group plc
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
